Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Onco-Innovations (ONNVF) has reported positive results from a December 2021 University of Alberta study on its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound used in combination with radiation therapy. The study focused on mice with colorectal cancer tumors, divided into three treatment groups receiving different combinations of treatments over 24 days.
The key finding revealed that the PNKP technology demonstrated effective cancer cell targeting while maintaining a low toxicity profile, even at therapeutic doses. Notably, no significant toxicity signs, including weight loss, were observed in any treatment group, including those receiving PNKP inhibitor-loaded nanoparticles with radiation.
This development is particularly significant as it suggests potential for developing safer cancer treatments with fewer side effects. The technology's minimal toxicity in preclinical animal models aligns with Health Canada's rigorous testing requirements for drug safety assessment.
Onco-Innovations (ONNVF) ha riportato risultati positivi da uno studio condotto nel dicembre 2021 dall'Università dell'Alberta sulla sua formulazione di nanoparticelle di seconda generazione del composto Polynucleotide Kinase 3'-Phosphatase (PNKP), utilizzato in combinazione con la terapia radiante. Lo studio si è concentrato su topi con tumori colorectal, suddivisi in tre gruppi di trattamento che hanno ricevuto diverse combinazioni di terapie per un periodo di 24 giorni.
Il risultato chiave ha rivelato che la tecnologia PNKP ha dimostrato un'efficace capacità di targeting delle cellule tumorali mantenendo un basso profilo di tossicità, anche a dosi terapeutiche. È importante notare che non sono stati osservati segni significativi di tossicità, inclusa la perdita di peso, in nessun gruppo di trattamento, compresi quelli che ricevevano nanoparticelle caricate con inibitori PNKP insieme alla radioterapia.
Questo sviluppo è particolarmente significativo poiché suggerisce il potenziale per sviluppare trattamenti oncologici più sicuri con meno effetti collaterali. La bassa tossicità della tecnologia nei modelli animali preclinici è in linea con i rigorosi requisiti di testing di Salute Canada per la valutazione della sicurezza dei farmaci.
Onco-Innovations (ONNVF) ha informado resultados positivos de un estudio de diciembre de 2021 de la Universidad de Alberta sobre su formulación de nanopartículas de segunda generación del compuesto Polynucleotide Kinase 3'-Phosphatase (PNKP) utilizado en combinación con la terapia de radiación. El estudio se centró en ratones con tumores de cáncer colorrectal, divididos en tres grupos de tratamiento que recibieron diferentes combinaciones de tratamientos durante 24 días.
El hallazgo clave reveló que la tecnología PNKP demostró una efectiva capacidad de dirigirse a las células cancerosas mientras mantenía un bajo perfil de toxicidad, incluso a dosis terapéuticas. Notablemente, no se observaron signos significativos de toxicidad, incluida la pérdida de peso, en ningún grupo de tratamiento, incluidos aquellos que recibieron nanopartículas cargadas con inhibidores de PNKP junto con radiación.
Este desarrollo es particularmente significativo ya que sugiere el potencial para desarrollar tratamientos contra el cáncer más seguros con menos efectos secundarios. La mínima toxicidad de la tecnología en modelos animales preclínicos se alinea con los rigurosos requisitos de prueba de Salud Canadá para la evaluación de la seguridad de los medicamentos.
Onco-Innovations (ONNVF)는 2021년 12월 앨버타 대학교에서 실시한 연구 결과, 방사선 요법과 병행하여 사용되는 두 번째 세대 나노입자 제형인 Polynucleotide Kinase 3'-Phosphatase (PNKP) 화합물에 대한 긍정적인 결과를 보고했습니다. 이 연구는 대장암 종양을 가진 쥐를 대상으로 하였으며, 24일 동안 다양한 치료 조합을 받은 세 개의 치료 그룹으로 나누어 진행되었습니다.
주요 발견은 PNKP 기술이 낮은 독성 프로필을 유지하면서 효과적으로 암 세포를 표적화하는 것으로 나타났습니다, 치료 용량에서도 마찬가지입니다. 특히 PNKP 억제제가 포함된 나노입자와 방사선을 함께 받은 치료 그룹에서도 체중 감소를 포함한 유의미한 독성 징후가 관찰되지 않았습니다.
이 발전은 부작용이 적은 더 안전한 암 치료제를 개발할 가능성을 제시하기 때문에 특히 중요합니다. 이 기술의 최소한의 독성은 약물 안전성 평가를 위한 건강 캐나다의 엄격한 시험 요구 사항과 일치합니다.
Onco-Innovations (ONNVF) a rapporté des résultats positifs d'une étude de décembre 2021 de l'Université de l'Alberta sur sa formulation de nanoparticules de deuxième génération du composé Polynucleotide Kinase 3'-Phosphatase (PNKP) utilisé en combinaison avec la radiothérapie. L'étude s'est concentrée sur des souris présentant des tumeurs colorectales, divisées en trois groupes de traitement recevant différentes combinaisons de traitements pendant 24 jours.
Le constat clé a révélé que la technologie PNKP a démontré une capacité efficace à cibler les cellules cancéreuses tout en maintenant un faible profil de toxicité, même à des doses thérapeutiques. Notamment, aucun signe de toxicité significatif, y compris la perte de poids, n'a été observé dans aucun groupe de traitement, y compris ceux recevant des nanoparticules chargées d'inhibiteurs PNKP avec radiation.
Ce développement est particulièrement significatif car il suggère un potentiel pour développer des traitements contre le cancer plus sûrs avec moins d'effets secondaires. La faible toxicité de cette technologie dans des modèles animaux précliniques est en accord avec les exigences rigoureuses de test de Santé Canada pour l'évaluation de la sécurité des médicaments.
Onco-Innovations (ONNVF) hat positive Ergebnisse aus einer Studie der Universität Alberta im Dezember 2021 zu seiner zweiten Generation von Nanopartikel-Formulierungen des Polynukleotid-Kinase 3'-Phosphatase (PNKP) Verbindungen berichtet, die in Kombination mit Strahlentherapie verwendet werden. Die Studie konzentrierte sich auf Mäuse mit kolorektalen Krebsgeschwülsten, die in drei Behandlungsgruppen unterteilt wurden, die über einen Zeitraum von 24 Tagen unterschiedliche Behandlungskombinationen erhielten.
Die wichtigste Erkenntnis war, dass die PNKP-Technologie eine effektive Zielgerichtetheit auf Krebszellen zeigte und gleichzeitig ein niedriges Toxizitätsprofil aufrechterhielt, selbst bei therapeutischen Dosen. Bemerkenswerterweise wurden in keiner der Behandlungsgruppen, einschließlich derjenigen, die mit PNKP-Inhibitor-beladenen Nanopartikeln und Strahlung behandelt wurden, signifikante Toxizitätszeichen, einschließlich Gewichtsverlust, beobachtet.
Diese Entwicklung ist besonders bedeutend, da sie das Potenzial für die Entwicklung sicherer Krebsbehandlungen mit weniger Nebenwirkungen nahelegt. Die minimale Toxizität der Technologie in präklinischen Tiermodellen entspricht den strengen Testanforderungen von Health Canada zur Bewertung der Arzneimittelsicherheit.
- Demonstrated effective cancer cell targeting with low toxicity profile
- No significant side effects observed in preclinical trials
- Successfully passed initial safety testing requirements for Health Canada
- Still in early preclinical testing phase
- Results to animal studies only
- Further extensive testing required before human trials
VANCOUVER, BC / ACCESS Newswire / March 26, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the "Technology") in combination with radiation therapy, which has demonstrated, in a December 2021 study[1] conducted by researchers at the University of Alberta, Canada, effective targeting of cancer cells in mice while, importantly, maintaining a low toxicity profile. The low toxicity observed in the study, even at therapeutic doses in mice with colorectal cancer, and especially when combined with radiation therapy, is particularly significant, as it suggests the potential for a solution with fewer side effects, which could lead to the development of safer and more effective treatment options.
As part of the study, mice implanted with colorectal cancer tumours (HCT116/PTEN+/+ tumours) were divided into three groups and received three separate injections over a 24-day period. Treatment groups included those receiving empty nanoparticles, empty nanoparticles with radiation, and PNKP inhibitor-loaded nanoparticles with radiation. Throughout the study, no significant signs of toxicity such as weight loss were detected in any group, including those treated with the nanoparticle formulation of the PNKP inhibitor in conjunction with radiation. [2]
A key factor in developing safer and more effective cancer treatments is ensuring a low toxicity profile. Onco's Technology has demonstrated minimal toxicity in preclinical animal models, which suggests its potential for use in advancing therapies that cause fewer side effects. In compliance with Health Canada regulations, drugs must undergo rigorous testing in both animal models (in vivo) and cell cultures (in vitro) to assess their safety and toxicity at doses aimed at achieving therapeutic effects.
"Establishing the safety of combination therapies is an important step in advancing cancer treatment. The findings from this study reinforce the strong safety profile of our PNKP technology in animal testing when used alongside radiation therapy. With low toxicity being a key factor in treatment development, these results provide a solid foundation for future research as we continue exploring the potential of this approach in upcoming studies," said Thomas O'Shaughnessy, CEO of the Company.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Technology, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize the Technology, the failure to receive regulatory approval in respect of the Technology, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[1] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920
[2] Sadat et al. Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage. Front Oncol. 2021 Dec 23;11:772920. doi: 10.3389/fonc.2021.772920
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What were the key findings of the University of Alberta study on ONNVF's PNKP technology?
How was the ONNVF PNKP study conducted on mice with colorectal cancer?
What makes ONNVF's PNKP technology potentially significant for cancer treatment?
When was the ONNVF PNKP technology study conducted and by whom?
